Po‐Hong Liu

3.6k total citations · 1 hit paper
97 papers, 2.5k citations indexed

About

Po‐Hong Liu is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Po‐Hong Liu has authored 97 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Hepatology, 60 papers in Epidemiology and 34 papers in Surgery. Recurrent topics in Po‐Hong Liu's work include Hepatocellular Carcinoma Treatment and Prognosis (60 papers), Liver Disease Diagnosis and Treatment (53 papers) and Liver Disease and Transplantation (20 papers). Po‐Hong Liu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (60 papers), Liver Disease Diagnosis and Treatment (53 papers) and Liver Disease and Transplantation (20 papers). Po‐Hong Liu collaborates with scholars based in United States, Taiwan and United Kingdom. Po‐Hong Liu's co-authors include Teh‐Ia Huo, Yi‐Hsiang Huang, Chia‐Yang Hsu, Cheng‐Yuan Hsia, Han‐Chieh Lin, Yun-Hsuan Lee, Chien‐Wei Su, Andrew T. Chan, Edward L. Giovannucci and Kana Wu and has published in prestigious journals such as Gastroenterology, PLoS ONE and Annals of Surgery.

In The Last Decade

Po‐Hong Liu

95 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women

2018 337 citations Po‐Hong Liu, Kana Wu et al. profile →

Peers

Countries citing papers authored by Po‐Hong Liu

Since Specialization

Citations

This map shows the geographic impact of Po‐Hong Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Po‐Hong Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Po‐Hong Liu more than expected).

Fields of papers citing papers by Po‐Hong Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Po‐Hong Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Po‐Hong Liu. The network helps show where Po‐Hong Liu may publish in the future.

Co-authorship network of co-authors of Po‐Hong Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Po‐Hong Liu. A scholar is included among the top collaborators of Po‐Hong Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Po‐Hong Liu. Po‐Hong Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing 2023 ·Cancer Epidemiology Biomarkers & Prevention ·Po‐Hong Liu, (unknown), Celette Sugg Skinner, Caitlin C. Murphy, (unknown), (unknown), (unknown), (unknown), Jacquelyn M. Lykken, Theodore R. Levin, Beverly B. Green, Erin E. Hahn, Noel Santini, Ethan A. Halm	2
2	Prognostic Prediction for Patients with Hepatocellular Carcinoma and Ascites: Role of Albumin-Bilirubin (ALBI) Grade and Easy (EZ)-ALBI Grade 2023 ·Cancers ·(unknown), Shu‐Yein Ho, Po‐Hong Liu, (unknown), Yi‐Hsiang Huang, Chien‐Wei Su, Ming‐Chih Hou, Teh‐Ia Huo	7
3	Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin–bilirubin grade 2022 ·International Journal of Clinical Oncology ·(unknown), Shu‐Yein Ho, Po‐Hong Liu, (unknown), Cheng‐Yuan Hsia, Yi‐Hsiang Huang, Chien‐Wei Su, (unknown), Rheun‐Chuan Lee, Ming‐Chih Hou, Teh‐Ia Huo	6
4	Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score 2022 ·Cancers ·Shu‐Yein Ho, Po‐Hong Liu, (unknown), Yi‐Hsiang Huang, (unknown), Chien‐Wei Su, Ming‐Chih Hou, Teh‐Ia Huo	6
5	Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis 2022 ·Journal of Gastrointestinal Cancer ·(unknown), Ammar Majeed, Anouk Dev, Guy D. Eslick, David J. Pinato, Hirofumi Izumoto, Atsushi Hiraoka, Teh‐Ia Huo, Po‐Hong Liu, Philip J. Johnson, Stuart K. Roberts	14
6	Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma 2021 ·Hepatology Research ·Shu‐Yein Ho, Po‐Hong Liu, Chia‐Yang Hsu, (unknown), Yi‐Hsiang Huang, Chien‐Wei Su, Cheng‐Yuan Hsia, Ping‐Hsing Tsai, Shih‐Jie Chou, Rheun‐Chuan Lee, Ming‐Chih Hou, Teh‐Ia Huo	16
7	Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization 2021 ·Journal of Gastroenterology and Hepatology ·Shu‐Yein Ho, Po‐Hong Liu, Chia‐Yang Hsu, (unknown), Yi‐Hsiang Huang, Chien‐Wei Su, Rheun‐Chuan Lee, Ping‐Hsing Tsai, Ming‐Chih Hou, Teh‐Ia Huo	29
8	Metavir Fibrosis Stage in Hepatitis C–Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve Models 2020 ·Journal of Gastrointestinal Surgery ·Shu‐Yein Ho, (unknown), Chia‐Yang Hsu, Po‐Hong Liu, Cheng‐Yuan Hsia, Yi‐Hsiang Huang, Teh‐Ia Huo	2
9	Albumin–Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization 2020 ·Digestive Diseases and Sciences ·Shu‐Yein Ho, Chia‐Yang Hsu, Po‐Hong Liu, Rheun‐Chuan Lee, (unknown), Yi‐Hsiang Huang, Chien‐Wei Su, Ming-Chih Hou, Teh‐Ia Huo	13
10	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma 2020 ·Liver International ·Po‐Hong Liu, Chia‐Yang Hsu, Chien‐Wei Su, Yi‐Hsiang Huang, Ming‐Chih Hou, Nicole E. Rich, Naoto Fujiwara, Yujin Hoshida, Amit G. Singal, Teh‐Ia Huo	31
11	Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade 2020 ·Cancers ·Shu‐Yein Ho, Chia‐Yang Hsu, Po‐Hong Liu, (unknown), Yi‐Hsiang Huang, Chien‐Wei Su, Rheun‐Chuan Lee, Ming-Chih Hou, Teh‐Ia Huo	10
12	Differential Survival Impact of Diabetes Mellitus on Hepatocellular Carcinoma: Role of Staging Determinants 2020 ·Digestive Diseases and Sciences ·Shu‐Yein Ho, (unknown), Chu-Chieh Chen, Po‐Hong Liu, Chia‐Yang Hsu, Yi‐Hsiang Huang, Hao-Jan Lei, Rheun‐Chuan Lee, Teh‐Ia Huo	5
13	Intake of Dietary Fiber, Fruits, and Vegetables and Risk of Diverticulitis 2019 ·The American Journal of Gastroenterology ·Wenjie Ma, Long H. Nguyen, Mingyang Song, Manol Jovani, Po‐Hong Liu, Yin Cao, Idy Tam, Kana Wu, Edward L. Giovannucci, Lisa L. Strate, Andrew T. Chan	40
14	Menopausal Hormone Therapy and Risk of Diverticulitis 2019 ·The American Journal of Gastroenterology ·Manol Jovani, Wenjie Ma, Amit D. Joshi, Po‐Hong Liu, Long H. Nguyen, Yin Cao, Idy Tam, Kana Wu, Edward L. Giovannucci, Andrew T. Chan, Lisa L. Strate	21
15	A New Prognostic Model Based on Albumin–Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria 2019 ·Digestive Diseases and Sciences ·Shu‐Yein Ho, Po‐Hong Liu, Chia‐Yang Hsu, Cheng‐Yuan Hsia, Yi‐Hsiang Huang, Chien‐Wei Su, Hao-Jan Lei, Rheun‐Chuan Lee, Ming-Chih Hou, Teh‐Ia Huo	11
16	Albumin‐bilirubin grade‐based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma 2019 ·Liver International ·Shu‐Yein Ho, (unknown), Po‐Hong Liu, Cheng‐Yuan Hsia, (unknown), Yi‐Hsiang Huang, (unknown), Chien‐Wei Su, Rheun‐Chuan Lee, Ming‐Chih Hou, Teh‐Ia Huo	24
17	Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation 2018 ·Scientific Reports ·Shu‐Yein Ho, Po‐Hong Liu, Chia‐Yang Hsu, Yi‐You Chiou, Chien‐Wei Su, Yun-Hsuan Lee, Yi‐Hsiang Huang, Fa‐Yauh Lee, Ming-Chih Hou, Teh‐Ia Huo	27
18	Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma 2018 ·BMC Cancer ·(unknown), Po‐Hong Liu, (unknown), Cheng‐Yuan Hsia, (unknown), Yun-Hsuan Lee, Yi‐You Chiou, (unknown), Yi‐Hsiang Huang, Teh‐Ia Huo	12
19	Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection 2018 ·Scientific Reports ·Shu‐Yein Ho, Po‐Hong Liu, Chia‐Yang Hsu, Cheng‐Yuan Hsia, Chien‐Wei Su, Yun-Hsuan Lee, Yi‐Hsiang Huang, Fa‐Yauh Lee, Ming-Chih Hou, Teh‐Ia Huo	32
20	Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization 2017 ·PLoS ONE ·Shu‐Yein Ho, Po‐Hong Liu, Chia‐Yang Hsu, Cheng‐Yuan Hsia, Yun-Hsuan Lee, Rheun‐Chuan Lee, Yi‐Hsiang Huang, Fa‐Yauh Lee, Ming-Chih Hou, (unknown), Teh‐Ia Huo	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact